Carvedilol PCD Pharma Franchise Company
Cafoli Lifecare offers a Carvedilol range of 7 tablet formulations, manufactured in WHO-GMP certified facilities. Distributors building a cardiovascular portfolio can secure district-wise monopoly franchise rights for this dual-acting alpha-beta blocker with full promotional support.
What is Carvedilol?
Carvedilol is a non-selective beta-blocker with additional alpha-1 blocking and antioxidant properties. By reducing heart rate and afterload it lowers blood pressure and cardiac workload, and it is one of the evidence-based beta-blockers proven to improve survival in chronic heart failure. Reference: MedlinePlus - Carvedilol.
Available Forms
The Cafoli Carvedilol portfolio is offered as oral Tablets across the commonly prescribed strengths for hypertension and heart-failure dosing. Contact us for current pack presentations and trade offers.
Therapeutic Applications
Carvedilol is prescribed for chronic stable heart failure, hypertension, angina and left-ventricular dysfunction after myocardial infarction. Prescribers include cardiologists, physicians and general practitioners managing cardiovascular disease.
Why Carvedilol is a High-Potential Molecule for Distributors
Carvedilol holds a firm, guideline-mandated place in heart-failure management, where therapy is lifelong and up-titrated over months, and it is also widely used in hypertension. That guideline-driven, chronic prescribing across a large and growing cardiac population gives distributors highly predictable, long-term refill volume.
Why Choose Cafoli Lifecare
Cafoli Lifecare offers monopoly franchise rights, WHO-GMP certified manufacturing, DCGI-approved formulations, a network of 1000+ franchise partners across India, and free promotional inputs.
References
- MedlinePlus: Carvedilol
- PubChem: Carvedilol
- PubMed: carvedilol in heart failure
Our formulations of Carvedilol find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: